[Special Stock] Notus Proves Corporate Value with COVID-19 Treatment Development... Korea's Largest CRO Premium

[Asia Economy Reporter Hyungsoo Park] Notus, the largest domestic contract research organization (CRO), is showing strong performance. As many major domestic pharmaceutical companies participate in developing treatments for coronavirus disease 2019 (COVID-19) with Notus, expectations for an increase in the company's value appear to be growing.

As of 11:35 a.m. on the 18th, Notus is trading at 29,300 KRW, up 9.12% compared to the previous trading day.

Leeon Pharmaceutical recently announced that it confirmed the antiviral efficacy of its COVID-19 treatment in suppressing viral replication. The joint research team of Leeon Pharmaceutical, GNPI Bioscience, and Notus confirmed the efficacy of a new COVID-19 drug candidate obtained in April in inhibiting viral replication without cytotoxic effects. Antiviral efficacy analysis tests observed viral replication suppression compared to the COVID-19 single treatment group. It was also proven that no cytotoxicity was observed in any of the test substance treatment groups.

Daewoong Therapeutics, a subsidiary of Daewoong Group, developed a new formulation (DWRX2003) last year that maintains the blood concentration of niclosamide. They have been promoting the development of treatments for intractable lung diseases through joint research with Notus. Daewoong Therapeutics is developing technology to treat COVID-19 by utilizing DWRX2003 with niclosamide to maintain blood concentration.

Daewoong Pharmaceutical and Daewoong Therapeutics confirmed a clear improvement in viral infection in animal efficacy tests of the COVID-19 treatment DWRX2003. Daewoong Therapeutics plans to continue nonclinical trials, including efficacy tests and toxicity tests, targeting additional animal models.

This content was produced with the assistance of AI translation services.